182
Participants
Start Date
December 20, 2012
Primary Completion Date
September 3, 2018
Study Completion Date
December 22, 2022
bevacizumab
Staring within 14 days of randomization, IV 10mg/kg every two weeks until disease progression.
radiation therapy
Starting with second dose of bevacizumab, 35 Gy in 10 fractions of 3.5 Gy each delivered on consecutive treatment days (typically 5 fractions per week).
University of Rochester, Rochester
Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh
Lancaster General Hospital, Lancaster
Radiation Therapy Oncology Group, Philadelphia
Cone Health Cancer Center, Greensboro
Medical University of South Carolina, Charleston
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
University of Alabama at Birmingham, Birmingham
Norton Health Care Pavilion - Downtown, Louisville
Summa Barberton Hospital, Barberton
Summa Akron City Hospital, Akron
IU Health Methodist Hospital, Indianapolis
Memorial Hospital of South Bend, South Bend
Radiation Oncology Associates PC, Fort Wayne
University of Michigan University Hospital, Ann Arbor
West Michigan Cancer Center, Kalamazoo
Bay Area Medical Center, Marinette
Saint Vincent Hospital, Green Bay
Saint Mary's Hospital, Green Bay
Washington University School of Medicine, St Louis
Nebraska Methodist Hospital, Omaha
Arizona Oncology Services Foundation, Phoenix
Arizona Oncology-Deer Valley Center, Phoenix
John Muir Medical Center, Walnut Creek
Queen's Medical Center, Honolulu
North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima
Yale University, New Haven
Maine Medical Center- Scarborough Campus, Scarborough
Lowell General Hospital, Lowell
University of Texas Medical Branch, Galveston
Door County Cancer Center, Sturgeon Bay
National Cancer Institute (NCI)
NIH
Radiation Therapy Oncology Group
NETWORK